Dosage Form: Tablet.
As a result of the sorbitol accumulation, epalrestat improves peripheral neuropathy. It’s typically used to treat diabetic peripheral neuropathy symptoms like numbness, discomfort, and odd vibration sensation/heart rate variability.
Epalrestat is an aldose reductase inhibitor. Aldose reductase inhibitors have different mechanisms of action, affecting the underlying disease process of diabetic neuropathy, although the degree of involvement of the polyol pathway has not been determined. The drug inhibits the accumulation of sorbitol in cells by inhibiting the action of aldose reductase, which converts glucose from sugar to sorbitol. Epalrestat can improve sensory and motor nerve conduction velocity and subjective symptoms of neuropathy.
In general, for adults, take 1 tablet (50 mg of the active ingredient) at a time, 3 times a day before meals. The dosage may be adjusted according to your age and symptoms.
Route of administration: Orally.
There are no known drug interactions and none well documented.
- If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
- If you are pregnant or breastfeeding.
- If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
The most commonly reported adverse reactions include abdominal pain, nausea, rash, itch, erythema and blister.
Pregnancy & Lactation:
Pregnancy category is not classified. FDA has not yet classified the drug into a specified pregnancy category.
Precautions & Warnings:
Your urinary color may turn yellowish brown or red due to color of the component of this medicine. Do not worry about the change.
Aldose reductase inhibitor
Keep out of the reach of children. Store away from direct sunlight, heat and moisture.
Manufactured by: Eskayef Pharmaceuticals Ltd.